- ClearPoint Neuro ( NASDAQ: CLPT ) expects Q4 revenue to increase 21% year-over-year to $5.2M compared to consensus estimate of $5.8M .
- Biologics and drug delivery revenue is estimated to grow 37% Y/Y to $2.3M, while functional neurosurgery products and services revenue increased to $2.3M, up 7% Y/Y.
- For full year 2022, the company expects to report record revenue of $20.6M (+26 Y/Y), below its own guidance and consensus estimate of $21.2M. It added multiple new biologics and drug delivery partners in the year to bring the total to more than 50 partners.
- Looking ahead, revenue is estimated to grow between $25M and $27M in 2023 in line with $26M estimate.
For further details see:
ClearPoint Neuro sees Q4 revenue below estimates